Study to Evaluate the Efficacy and Safety of Combination Aliskiren/Amlodipine in Patients Not Adequately Responding to Aliskiren Alone

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT00777946

Recruitment Status : Completed

First Posted : October 22, 2008

Results First Posted : June 15, 2011

Last Update Posted : July 12, 2011

Sponsor:

Information provided by:

Novartis

Study Description

Brief Summary:

This study will assess the safety and efficacy of combination aliskiren/amlodipine in patients not adequately controlled with aliskiren alone

Condition or disease	Intervention/treatment	Phase
Hypertension	Drug: Aliskiren 300 mg Drug: Aliskiren/Amlodipine 300/5 mg Drug: Aliskiren/Amlodipine 300/10 mg Drug: Placebo to Aliskiren Drug: Placebo to Aliskiren/Amlodipine	Phase 3

Study Design


Study Type :	Interventional (Clinical Trial)
Actual Enrollment :	818 participants
Allocation:	Randomized
Intervention Model:	Parallel Assignment
Masking:	Double (Participant, Investigator)
Primary Purpose:	Treatment
Official Title:	A Randomized, Eight-week Double-blind, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Aliskiren / Amlodipine (300/5 mg and 300/10 mg) in Comparison With Aliskiren 300 mg in Patients With Essential Hypertension Not Adequately Responsive to Aliskiren 300 mg Monotherapy
Study Start Date :	October 2008
Actual Primary Completion Date :	May 2009
Actual Study Completion Date :	May 2009

Resource links provided by the National Library of Medicine

Drug Information available for: Amlodipine Amlodipine besylate Aliskiren

U.S. FDA Resources

Arms and Interventions

Arm	Intervention/treatment
Experimental: Aliskiren 300 mg/Amlodipine 5 mg Participants received 1 Aliskiren/Amlodipine 300/5mg tablet + 1 Placebo to Aliskiren tablet once daily in the morning for 8 weeks.	Drug: Aliskiren/Amlodipine 300/5 mg Aliskiren/Amlodipine 300/5 mg tablet taken orally once a day with a glass of water. Drug: Placebo to Aliskiren Placebo to Aliskiren tablet taken orally once a day.
Experimental: Aliskiren 300 mg/Amlodipine 10 mg Participants received 1 Aliskiren/Amlodipine 300/10 mg tablet + 1 Placebo to Aliskiren tablet orally once daily in the morning for 8 weeks.	Drug: Aliskiren/Amlodipine 300/10 mg Aliskiren/Amlodipine 300/10 mg taken orally once a day with a glass of water. Drug: Placebo to Aliskiren Placebo to Aliskiren tablet taken orally once a day.
Active Comparator: Aliskiren 300 mg Participants received 1 Aliskiren 300 mg tablet + 1 Placebo to Aliskiren/Amlodipine tablet orally once daily in the morning for 8 weeks.	Drug: Aliskiren 300 mg Aliskiren 300 mg tablet taken orally once a day with a glass of water. Drug: Placebo to Aliskiren/Amlodipine Placebo to Aliskiren/Amlodipine taken orally once a day.

Outcome Measures

Primary Outcome Measures :

Change From Baseline to End of Study in the Mean Sitting Diastolic Blood Pressure (msDBP) [ Time Frame: Baseline, End of Study (Week 8) ]
After the patient had been sitting for 5 minutes, systolic and diastolic blood pressures were measured 3 times using the automatic Blood Pressure monitor and appropriate size cuff. The repeat sitting measurements were made at 1-2 minute intervals and the mean of these 3 sitting blood pressure measurements was used as the average sitting blood pressure for that visit. The difference of the msDBP at baseline from the msDBP at 8 weeks was calculated using an Analysis of Covariance (ANCOVA) model with baseline as a covariate and treatment and region as two factors.

Secondary Outcome Measures :

Change From Baseline to End of Study in the Mean Sitting Systolic Blood Pressure (msSBP) [ Time Frame: Baseline, End of Study (Week 8) ]
After the patient had been sitting for 5 minutes, systolic and diastolic blood pressures were measured 3 times using the automatic Blood Pressure monitor and appropriate size cuff. The repeat sitting measurements were made at 1-2 minute intervals and the mean of these 3 sitting blood pressure measurements was used as the average sitting blood pressure for that visit. The difference of the msSBP at baseline from the msSBP at 8 weeks was calculated using an ANCOVA model with baseline as a covariate and treatment and region as two factors.
Number of Participants With Serious Adverse Events and Adverse Events [ Time Frame: 8 weeks ]
The number of participants with any Serious Adverse Event and the number of participants with Adverse Events in any system organ class.

Additional information about Adverse Events can be found in the Adverse Event Section.
Percentage of Participants Achieving Blood Pressure Control [ Time Frame: 8 weeks ]
After the patient had been sitting for 5 minutes, with the back supported and both feet placed on the floor, systolic and diastolic blood pressures were measured 3 times using the automatic Blood Pressure monitor and appropriate size cuff. The repeat sitting measurements were made at 1-2 minute intervals and the mean of these 3 sitting blood pressure measurements was used as the average sitting blood pressure for that visit.

Blood Pressure control was defined as having a mean sitting Diastolic Blood Pressure <90 and a mean sitting Systolic Blood Pressure <140.
Percentage of Participants Achieving a Diastolic Blood Pressure Response [ Time Frame: 8 weeks ]
After the patient had been sitting for 5 minutes, with the back supported and both feet placed on the floor, systolic and diastolic blood pressures were measured 3 times using the automatic Blood Pressure monitor and appropriate size cuff. The repeat sitting measurements were made at 1-2 minute intervals and the mean of these 3 sitting blood pressure measurements was used as the average sitting blood pressure for that visit.

A Diastolic Blood Pressure Response was defined as a mean sitting Diastolic Blood Pressure (msDBP) <90 mmHg or a ≥ 10 mmHg reduction in msDBP from baseline.
Percentage of Participants Achieving a Systolic Blood Pressure Response [ Time Frame: 8 weeks ]
After the patient had been sitting for 5 minutes, with the back supported and both feet placed on the floor, systolic and diastolic blood pressures were measured 3 times using the automatic Blood Pressure monitor and appropriate size cuff. The repeat sitting measurements were made at 1-2 minute intervals and the mean of these 3 sitting blood pressure measurements was used as the average sitting blood pressure for that visit.

A Systolic Blood Pressure Response was defined as a mean sitting Systolic Blood Pressure (msSBP) <140 mmHg or a ≥ 20 mmHg reduction in msSBP from baseline.

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:	18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Newly diagnosed patients or patients who have not been treated for hypertension within the 4 weeks prior to Visit 1 must have a mean sitting Diastolic Blood Pressure (msDBP) ≥ 95 mmHg and < 110 mmHg at Visits 1 and 2
Patients who have been treated for hypertension within the 4 weeks prior to - Visit 1 must have a msDBP ≥ 90 mmHg and < 110 mmHg at Visit 2
All patients must have a msDBP ≥ 90 mmHg and < 110 mmHg at Visit 4

Exclusion Criteria:

Severe hypertension
Pregnant or nursing (lactating) women
Women of child-bearing potential
Previous or current diagnosis of heart failure New York Heart Association (NYHA Class II-IV)
Serum potassium ≥ 5.3 mEq/L (mmol/L) at Visit 1
Uncontrolled Type 1 or Type 2 diabetes mellitus
Hypersensitivity to renin inhibitors, calcium channel blockers, or to drugs with Similar chemical structures
History of hypertensive encephalopathy or cerebrovascular accident, or history of transient ischemic attack (TIA), myocardial infarction, coronary bypass surgery, or any percutaneous coronary intervention

Other protocol-defined inclusion/exclusion criteria may apply.

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00777946

Locations


Estonia
Investigative site
Estonia, Estonia
France
Investigative site
France, France
Iceland
Investigative Site
Iceland, Iceland
India
Investigative Site
India, India
Italy
Investigative site
Italy, Italy
Korea, Republic of
Investigative Site
Republic of Korea, Korea, Republic of
Lithuania
Investigative Site
Lithuania, Lithuania
Spain
Investigative Site
Spain, Spain
Venezuela
Investigative Site
Venezuela, Venezuela

Sponsors and Collaborators

Novartis

Investigators


Study Chair:	Novartis	Novartis

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Glorioso N, Thomas M, Troffa C, Argiolas G, Patel S, Baek I, Zhang J. Antihypertensive efficacy and tolerability of aliskiren/amlodipine single- pill combinations in patients with an inadequate response to aliskiren monotherapy. Curr Vasc Pharmacol. 2012 Nov;10(6):748-55.


Responsible Party:	External Affairs, Novartis
ClinicalTrials.gov Identifier:	NCT00777946 History of Changes
Other Study ID Numbers:	CSPA100A2303
First Posted:	October 22, 2008 Key Record Dates
Results First Posted:	June 15, 2011
Last Update Posted:	July 12, 2011
Last Verified:	June 2011

Keywords provided by Novartis:


Aliskiren, Amlodipine, Non-responder to aliskiren

Additional relevant MeSH terms:


Hypertension Vascular Diseases Cardiovascular Diseases Amlodipine Antihypertensive Agents	Calcium Channel Blockers Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Vasodilator Agents

To Top